ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
New leadership team announced at NATHEALTH Annual General Meeting 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated